TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41017

Peptide_Name

FLAK50 T5

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FAKLLAKLAKKSL-NH2

FASTA

>TPDB41017|Anticancer|length=13
FAKLLAKLAKKSL-NH2

Formula C69H123N17O15

Absent Amino Acids RNDCEQGHIMPTWYV

Common Amino Acids LK

Mass 1430.84

PI 11.00

Basic Residues 4

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +4

Boman Index 0.21

Hydrophobicity 0.538

Aliphatic Index 143.08

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 1

number

3

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

4

L

4

K

0

M

1

F

0

P

1

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 4 K: 4 M: 0 F: 1 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0

Length

13

Formula

C69H123N17O15

Mass

1430.84

PI

11.00

Net Charge

+4

Boman Index

0.21

Hydrophobicity

0.538

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

FLAK peptides

Evidence 1 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =440 µg/ml

Detail Source Activity Anticancer

Activity Measurement 440 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =400 µg/ml

Detail Source Activity Anticancer

Activity Measurement 400 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =535 µg/ml

Detail Source Activity Anticancer

Activity Measurement 535 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =770 µg/ml

Detail Source Activity Anticancer

Activity Measurement 770 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =>1000 µg/ml

Detail Source Activity Anticancer

Activity Measurement >1000 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =610 µg/ml

Detail Source Activity Anticancer

Activity Measurement 610 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2